Bergenbio second quarter results 2024: solid clinical and financial progress

Bergen, norway , aug. 21, 2024 /prnewswire/ -- bergenbio asa (ose: bgbio), a clinical-stage biopharmaceutical company developing novel, selective axl kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended june 30, 2024, and provided a business update. highlights, including post period: bgbc016 1l nsclc stk11m study continues to progress as planned.
TEM Ratings Summary
TEM Quant Ranking